SecBot SecBot
Biotech Drug Report Generated Oct 24, 2026

Tabirafusp alfa tedromer

KOD·Kodiak Sciences Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 3
Time to market
Unknown, DAYBREAK Phase 3 readout is positive, but Tabirafusp (KSI-501) still requires regulatory review and a separate Phase 3 ALTO study in DME. If prioritized, potential approval could be 2-3+ years out.
Why 4/10
The pivotal DAYBREAK Phase 3 readout for Tabirafusp alfa tedromer (KSI-501) in wet AMD already occurred on September 28, 2026, the binary event has passed. The next hard dated catalyst for this specific drug is not yet dated, the ALTO Phase 3 study of KSI-501 in DME is ongoing but has no announced topline readout date. With the primary binary catalyst behind it, impactScore is 4 per the rubric (post-pivotal-readout stage.
Actionable Insight NEUTRAL

The DAYBREAK Phase 3 readout (Sept 28, 2026) was the defining binary catalyst for Tabirafusp, it was a clear success, driving the stock from ~$32 to ~$90. The next catalysts are the PEAK Phase 3 readout for KSI-101 (Dec 2026) and the Zenkuda BLA submission (Q4 2026), but these are separate pipeline assets. For Tabirafusp specifically, watch for the ALTO Phase 3 study in DME and any regulatory path updates. The stock now trades near analyst targets ($103-$145 range) with ~39% implied upside to the mean target of $122.

Price Chart

Loading chart...

Executive Summary

Tabirafusp alfa tedromer (KSI-501) is Kodiak Sciences' bispecific antibody for wet age-related macular degeneration, tested in the pivotal DAYBREAK Phase 3 study (NCT06556368) alongside tarcocimab tedromer (Zenkuda) vs aflibercept. The DAYBREAK topline results were announced September 28, 2026, a resounding success, the stock surged from ~$32 to ~$90 in a single day (opening $61.70, high $95.77, close $89.92 on 38.5M shares). The stock now trades at $87.63 with strong analyst support (9/9 Buy/Strong Buy, mean target $121.67, implied 39% upside. However, the binary catalyst has already been priced in, the company remains pre-revenue with $125.9M cash burning ~$42M/quarter, and a $350M ATM overhang from the October 2026 S-3ASAR filing creates dilution risk. The next catalysts are the PEAK Phase 3 readout (KSI-101 in MESI, December 2026) and Zenkuda BLA submission (Q4 2026).

How It Works

Tabirafusp alfa tedromer (KSI-1351) is a bispecific antibody designed to treat wet age-related macular degeneration (wet AMD), a leading cause of blindness. It targets two disease pathways simultaneously, VEGF (a protein that drives abnormal blood vessel growth) and another inflammatory target, using Kodiak's ABC (Antibody Biopolymer Conjugate) platform designed to enable longer-lasting treatment effects, potentially allowing patients to receive injections less frequently than current standard-of-care drugs like Eylea and Vabysmo.

Trial Status

The DAYBREAK Phase 3 study (NCT06556368) in wet AMD is ACTIVE_NOT_RECRUITING with primary completion estimated August 2026 (actual completion estimated 2027-2026). Topline results were presented September 28, 2026 and were strongly positive, stock surged ~178% in a single day. The ALTO Phase 3 study of KSI-501 in diabetic macular edema (DME) is ongoing.

The Two-Sided Case

▲ Bull Case5
DAYBREAK Phase 3 results (Sept 28, 2026) were strongly positive, the stock opened at $61.70 from a ~$32 close, hitting $95.83 intraday on 38.5M shares volume, suggesting strong efficacy vs aflibercept in wet AMD.
Analyst consensus is strongly bullish: 9 of 9 analysts rate Buy/Strong Buy, with a mean price target of $121.67 (high $145, low $103), implying ~39% upside from $87.63.
Baker Bros. Advisors bought heavily into the DAYBREAK readout, purchasing ~$30M+ in stock on Sept 28-29 at $84-$90, signaling strong informed conviction.
The ABC platform (antibody-biopolymer conjugate) could enable longer-dosing regimens vs current standard-of-care, a major commercial advantage if replicated in Phase 3.
Short interest was 14.9% of shares outstanding (9.4M shares, 1.8 days to cover) as of Sept 30, 2026 settlement, creating potential short-squeeze dynamics.
▼ Bear Case5
The DAYBREAK readout is already priced in, the stock surged from ~$32 to ~$90 on Sept 28, leaving limited upside from here unless follow-on data surprises positively.
Kodiak has no approved products and an accumulated deficit of ~$1.68B. Cash of $125.9M (June 30, 2026) is burning at ~$42M/quarter, likely requiring dilutive financing before reaching profitability.
The company filed an S-3ASR shelf and an ATM agreement for up to $350M in stock sales (Oct 20, 2026), creating persistent dilution overhang.
Tabirafusp (KSI-501) still needs to navigate a separate Phase 3 ALTO study in DME and eventual regulatory review, it is not yet approvable.
Competition in wet AMD is intense: Regeneron's Eylea, Roche's Vabysmo (faricimab), and other anti-VEGF therapies are well-established with multi-billion-dollar franchises.

Upcoming Catalysts

  • PEAK Phase 3 topline data for KSI-101 in MESI (December 2026)
  • BLA submission for Zenkuda (tarcocimab tedromer) in Q4 2026
  • ALTO Phase 3 study of KSI-501 in DME, topline readout (no date yet)
  • Potential regulatory updates on Tabirafusp/KSI-501 path

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Kodiak Sciences Inc. S-3ASR KOD ·Originating report

Sources · 4

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 prnewswire.com